Novel drug delivery systems and significance in respiratory diseases

Mishra, Brahmeshwar; Singh, Juhi

doi:10.1016/b978-0-12-820658-4.00004-2

Cited by 38 publications

(11 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DDSs for asthma currently in preclinical development include alternatives to dry powder inhalers such as liposomes, microspheres and polymeric micelles. These systems have the potential to reduce the dosing frequency by enhancing deposition efficiency and reducing the rate of clearance from the lungs 196 , 197 .…”

Section: Trends In Adherence By Disease Typementioning

confidence: 99%

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

Baryakova

Pogostin

Langer

et al. 2023

Nat Rev Drug Discov

126

View full text Add to dashboard Cite

Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ineffective. Formulating a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitigate many common impediments to adherence, including frequent dosing, adverse effects and a delayed onset of action. Existing DDSs have already positively influenced patient acceptability and improved rates of adherence across various disease and intervention types. The next generation of systems have the potential to instate an even more radical paradigm shift by, for example, permitting oral delivery of biomacromolecules, allowing for autonomous dose regulation and enabling several doses to be mimicked with a single administration. Their success, however, is contingent on their ability to address the problems that have made DDSs unsuccessful in the past.

show abstract

Section: Trends In Adherence By Disease Typementioning

confidence: 99%

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

Baryakova

Pogostin

Langer

et al. 2023

Nat Rev Drug Discov

126

View full text Add to dashboard Cite

show abstract

“…However, the rapid clearance mechanism, drug deposition, and instability mechanism present problems with this method. The effectiveness of pulmonary delivery systems is further influenced by additional elements such as the kind of inhaler device, patient compatibility, consistent device delivery, and inhaler technique [ 96 ]. In order to address these problems, nanotechnology has been used in pulmonary delivery systems, targeting the direct intake of aerosols into the respiratory epithelium and epithelial cells.…”

Section: Xg-based Systems For the Delivery Of Drugsmentioning

confidence: 99%

Advances in Xanthan Gum-Based Systems for the Delivery of Therapeutic Agents

et al. 2023

View full text Add to dashboard Cite

In the last three decades, polymers have contributed significantly to the improvement of drug delivery technologies by enabling the controlled and sustained release of therapeutic agents, versatility in designing different delivery systems, and feasibility of encapsulation of both hydrophobic and hydrophilic molecules. Both natural and synthetic polymers have been explored for the delivery of various therapeutic agents. However, due to the disadvantages of synthetic polymers, such as lack of intrinsic biocompatibility and bioactivity, hydrophobicity, and expensive and complex procedure of synthesis, there is a move toward the use of naturally occurring polymers. The biopolymers are generally derived from either plants or microorganisms and have shown a wide range of applications in drug administration due to their hydrophilic nature, biodegradability, biocompatibility, no or low toxicity, abundance, and readily available, ease of chemical modification, etc. This review describes the applications of a biopolymer, xanthan gum (XG), in the delivery of various therapeutic agents such as drugs, genetic materials, proteins, and peptides. XG is a high molecular weight, microbial heteropolysaccharide and is produced as a fermented product of Gram-negative bacteria, Xanthomonas campestris. Traditionally, it has been used as a thickener in liquid formulations and an emulsion stabiliser. XG has several favourable properties for designing various forms of drug delivery systems. Furthermore, the structure of XG can be easily modified using different temperature and pH conditions. Therefore, XG and its derivatives have been explored for various applications in the food, pharmaceutical, and cosmetic industries.

show abstract

“…Additionally, administering drugs via the pulmonary route also demands that the drugs survive the shear forces exerted upon them during the aerosolization process [ 103 , 105 ]. Protecting inhaled therapeutics within nanoparticle shells such as LNPs serves to delay degradation, increase the bioavailability of intact compounds, and improve pharmacokinetic profiles [ 14 , 62 , 108 , 123 , 124 ].…”

Section: Advantages Of Inhaled Lnp Therapeuticsmentioning

confidence: 99%

Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics

Leong

2022

Biomedicines

View full text Add to dashboard Cite

Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery. With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 pandemic, investigations into applying LNPs to deliver inhaled therapeutics directly to the lungs are underway. The progress in LNP development as well as the recent pre-clinical studies in three main classes of inhaled encapsulated drugs: small molecules, nucleic acids and proteins/peptides will be discussed. The advantages of the pulmonary drug delivery system such as reducing systemic toxicity and enabling higher local drug concentration in the lungs are evaluated together with the challenges and design considerations for improved formulations. This review provides a perspective on the future prospects of LNP-mediated delivery of inhaled therapeutics for respiratory diseases.

show abstract

Novel drug delivery systems and significance in respiratory diseases

Cited by 38 publications

References 70 publications

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

Advances in Xanthan Gum-Based Systems for the Delivery of Therapeutic Agents

Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics

Contact Info

Product

Resources

About